How BTC Health’s $5M ECMO Win Fuels Its 25% Revenue Surge
BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.
- 25% revenue growth to $10.2 million in FY25
- Secured $5 million ECMO contract with Royal Children’s Hospital
- Positive adjusted EBITDA of $0.2 million achieved
- Acquisition of Corcym’s heart valve business integrated
- Expanded product portfolio with over 240 active lines
Strong Financial Performance Amid Diversification
BTC Health Limited (ASX, BTC) has delivered a compelling FY25 performance, reporting a 25% increase in revenue to $10.2 million. This growth reflects the company’s strategic focus on diversifying its medical product portfolio across acute pain management, neurospinal, cardiovascular, and pharmaceutical sectors. Notably, BTC Health achieved a positive adjusted EBITDA of $0.2 million and a statutory profit of $4 million, marking a significant improvement from prior years.
The company’s financial results underscore the effectiveness of its multi-pronged approach, combining established brands with innovative medical devices and specialty pharmaceuticals. This strategy has allowed BTC Health to build resilience and capitalize on rising healthcare spending driven by ageing populations and technological advancements.
Key Contract Wins and Strategic Acquisitions
A highlight of the year was securing a $5 million, five-year contract to supply Extracorporeal Membrane Oxygenation (ECMO) equipment and consumables to Melbourne’s Royal Children’s Hospital. ECMO is a critical, high-cost intervention for patients with severe cardiac and respiratory failure, and BTC Health’s exclusive distribution rights in Australia and New Zealand position it as a key player in this niche market.
Additional orders, such as the $0.5 million supply to the Women’s and Children’s Hospital in Adelaide, and ongoing trials at other hospitals, signal growing adoption of BTC’s ECMO products. The company also successfully integrated Corcym’s Australia/New Zealand heart valve business, expanding its footprint in cardiothoracic medical devices with products like the Perceval Plus tissue valve and Memo4D mitral ring.
Expanding Product Range and Market Reach
BTC Health’s portfolio now includes over 240 active products, supported by four new partnership agreements in FY25. The company’s distribution network reaches more than 500 metropolitan hospitals daily and services regional hospitals within 48 hours, covering over 1,450 hospitals across Australia and New Zealand.
Its specialty pharma division continues to grow, with extended licensing agreements such as the indefinite extension with Arna Pharma for Bronchitol and Aridol, treatments for cystic fibrosis and other niche conditions. The company is also transitioning customers to newer-generation infusion pumps, which offer safety and efficacy benefits in post-operative pain management.
Outlook and Strategic Priorities for FY26
Looking ahead, BTC Health aims to sustain double-digit revenue growth by winning additional ECMO hospital contracts and expanding the utilisation of heart valve products in established centres. The company plans to broaden its neurospinal product customer base and enhance its specialty pharmaceutical offerings.
Management targets improved bottom-line performance with a pathway toward sustainable profitability, building on the positive EBITDA delivered in FY25. The company’s agile culture and strong partnerships with multinational innovators underpin its confidence in capturing further market share in the competitive healthcare sector.
Bottom Line?
BTC Health’s FY25 momentum sets the stage for a pivotal year ahead as it seeks to convert growth into sustained profitability.
Questions in the middle?
- How will BTC Health manage risks associated with reliance on key hospital contracts like ECMO?
- What new pharmaceutical products are in the pipeline following the Arna Pharma partnership extension?
- Can BTC Health maintain its double-digit growth amid increasing competition in specialty medical devices?
